Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nordazepam→

Nordazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1088-11-5
Molecular formula
C15H11ClN2O
Molecular weight
270.71 g/mol
Drug class
Benzodiazepineactive metabolite of several benzodiazepines
Mechanism of action
Positive allosteric modulator of GABAA receptor complexes at the benzodiazepine binding site, enhancing GABA-mediated chloride-channel opening and neuronal inhibition.
Indications / reported uses
  • Anxiolytic and sedative effects are associated with nordazepam as an active metabolite of diazepam and other benzodiazepines; it is not generally marketed as a stand-alone API in many jurisdictions

Sources: NLM MeSH — Nordazepam · PubMed — Nordazepam pharmacology · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Benzodiazepine; active metabolite of several benzodiazepines

Mechanism of action

Positive allosteric modulator of GABAA receptor complexes at the benzodiazepine binding site, enhancing GABA-mediated chloride-channel opening and neuronal inhibition.

General use cases

  • Anxiolytic and sedative effects are associated with nordazepam as an active metabolite of diazepam and other benzodiazepines; it is not generally marketed as a stand-alone API in many jurisdictions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Nordazepam Environmental Risk Assessment (ERA) (the Nordazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.